News & Updates
Showing Multidisciplinary articles
Showing

Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.

Rising cases of community-acquired E. coli UTI in children a cause for concern
A recent study has found an increasing prevalence of community-acquired (CA) urinary tract infection (UTI) by emerging spectrum-β-lactamase-producing (ESBL) E. coli in children, with most isolates showing resistance to multiple drugs.

Endometrioma ups risk of failing antibiotic treatment for pelvic inflammatory disease
Among women with pelvic inflammatory disease, the presence of endometrioma is associated with a lower likelihood of responding to antibiotic treatment and a higher risk of surgical intervention, according to a study.

Treat childhood obesity promptly—AAP
Paediatricians and other healthcare providers should treat childhood obesity immediately and at the highest level of intensity appropriate for and available to children, according to the new guideline published by the American Academy of Pediatrics (AAP).

Counselling, pamphlets boost flu vaccine intake in SG
Use of educational pamphlets alone and individualized counselling (IC) both lead to improved uptake of influenza vaccination, reports a Singapore study, noting that IC is not superior to pamphlets alone in increasing uptake.

GLP-1 agonists induce weight loss in diabetic patients with obesity
Initiation of a glucagon-like peptide-1 (GLP-1) agonist at standard glycaemic control doses may result in modest weight loss through 72 weeks in patients with overweight or obesity and type 2 diabetes, suggest the results of a real-world study.


